This biotechnology startup is developing miRNA-based therapeutic products that target gene expression in the joint microenvironment to treat degenerative articular diseases. By utilizing small RNAs, the company aims to modify disease progression and provide a new treatment pathway for patients suffering from these conditions.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Osteoarthritis (OA) affects millions worldwide, causing cartilage deterioration in joints, leading to pain, stiffness, and impaired movement. Current treatments offer limited relief, and there is no cure for this debilitating condition, which significantly impacts mobility and quality of life.
Solution
Dharma Bioscience is developing miRNA-based therapeutics to address the underlying causes of osteoarthritis by stimulating cartilage regeneration. Their approach involves locally injecting a unique combination of modified microRNAs (miRNAs) into the affected joints to modulate the cellular microenvironment. These miRNAs work by restoring the balance of cell differentiation into cartilage, activating interconnected signaling networks, and promoting long-term tissue regeneration. The therapy aims to reprogram diseased cells to restore cartilage production, reduce pain and inflammation, and ultimately decrease the need for joint replacement surgeries.
Target Audience
The primary target audience includes individuals suffering from osteoarthritis, orthopedic specialists, and medical professionals focused on regenerative medicine and innovative treatments for joint diseases.
Features
- Modified miRNAs with high stability for long-lasting therapeutic effects
- Auto-catalytic mechanism for self-enhancing and propagating healing effects
- Highly-silencing capability to precisely target and regulate key genes involved in cartilage repair
- Minimized off-target effects for concentrated therapeutic action and reduced potential side effects
- Advanced miRNA diagnostics to identify specific patient needs for targeted treatment
- Proprietary poli-miRs formulation encapsulating specific miRNAs within nanoparticles
- Promotion of stable cell differentiation and tissue repair through optimized miRNA mix